Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616032 | 0.94 | TERT (0.44) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL30675546 | 0.92 | TERT (0.43) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL29757022 | 0.90 | TERT (0.47) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL2887200 | 0.90 | TERT (0.52) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL2887196 | 0.90 | TERT (0.52) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL29655322 | 0.89 | FOLH1 (0.52) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL29286384 | 0.89 | FOLH1 (0.50) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL29286382 | 0.89 | FOLH1 (0.50) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL30697803 | 0.88 | FOLH1 (0.59) | TERTGSRGNAI3GNAO1GNAI1 | |
| SCHEMBL29474449 | 0.88 | FOLH1 (0.47) | TERTGSRFOLH1PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | claimed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | claimed |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | BIORA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| WO-2023019333-A1 | MACROCYCLIC MIMETIC ANTAGONISTS WITH BIOLOGICAL ACTIVITY, USES THEREOF AND COMPOSITIONS | NOVAGEIA BIOTECNOLOGIA LTDA (BR) | 2023-02-23 | — | — | WO | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-108203457-B | Antithrombotic small peptide omega KWR for targeted inhibition of platelet aggregation | 山西医科大学 | 2022-09-06 | — | — | CN | disclosed |
| US-20220273196-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | FABP2, SI, MLNR | TERT 3592/4885GSR 610/4885GNAI3 243/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | TERT 608/4885GSR 989/4885GNAI3 3777/4885 |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | TERT 1621/4885GSR 11/4885GNAI3 4024/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | TERT 1621/4885GSR 11/4885GNAI3 4024/4885 |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | SI, VIP, MLN | TERT 3313/4885GSR 392/4885GNAI3 1348/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | TERT 1621/4885GSR 11/4885GNAI3 4024/4885 |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | FABP2, SI, MLNR | TERT 3592/4885GSR 610/4885GNAI3 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.